1. Field of the Invention
The present invention relates to a microfluidic system, and more particularly, to an anesthetic sensing optical microfluidic chip system.
2. Description of the Prior Art
Recently, since the anesthetic is very important in the clinical medicine region, the researches related to the anesthetic have been increased. For example, propofol (2,6-di-isopropylphenol) is an intravenous anesthetic and widely used in induction of anesthesia, total intravenous anesthesia and sedation of intensive care unit patients.
In order to detect the concentration of propofol in blood of human body, the high-performance liquid chromatography and/or the high-performance gas chromatography are conventionally used. However, not only the high-performance liquid chromatography and/or gas chromatography are very expensive and not ease of access, but also the detecting processes performed by the high-performance liquid chromatography and/or gas chromatography are time-consuming and not a real-time detection. Therefore, the conventional high-performance liquid chromatography and/or gas chromatography are not convenient for the doctor and patient to use. Clinically, a more convenient access to monitor the propofol concentration in blood is needed to avoid the adverse effects produced by excessive or insufficient propofol.
Therefore, the invention provides an anesthetic sensing optical microfluidic chip system to solve the aforementioned problems.
The invention provides an anesthetic sensing optical microfluidic chip system. One preferred embodiment of the invention is an anesthetic sensing optical microfluidic chip system. In this embodiment, the anesthetic sensing optical microfluidic chip system includes a biochip, a light source, and a detector. The biochip includes a substrate, a micro-channel, and a molecularly imprinted biosensor. The micro-channel is bonded beyond the substrate. The molecularly imprinted biosensor is disposed in the micro-channel, and a surface of the molecularly imprinted biosensor has a plurality of imprinted sites.
When a sample including a plurality of anesthetic molecules is injected into the micro-channel and flowing through the surface of the molecularly imprinted biosensor, some of the anesthetic molecules are captured by the imprinted sites. The light source emits a sensing light to the plastic biochip, and the detector receives the sensing light passing through the imprinted sites on the surface of the molecularly imprinted biosensor and generates a detecting result based on the received sensing light.
In practical applications, the anesthetic is propofol (2,6-di-isopropylphenol) and the molecularly imprinted biosensor is made of polymer. The plurality of imprinted sites on the surface of the molecularly imprinted biosensor is formed by processing the steps of polymer combination, polymerization, and extraction in order.
Compared with the prior art, the novel low-cost anesthetic sensing optical microfluidic chip system with molecularly imprinted biosensor disclosed by this invention has many advantages of compact size, high sensitivity, low cost, and fast response. With this anesthetic sensing optical microfluidic chip system, a real-time propofol concentration detection can be achieved and the propofol concentration can be also adjusted according to the result of the real-time propofol concentration detection. Additionally, since the biochip used in the anesthetic sensing optical microfluidic chip system is cheap and can be disposable, the mutual contamination occurred between several samples in the same large-scale liquid chromatography and/or gas chromatography can be effectively avoided. By doing so, the doctor can clinically control the propofol concentration more accurately and the safety of the patient can be further ensured.
The objective of the present invention will no doubt become obvious to those of ordinary skill in the art after reading the following detailed description of the preferred embodiment, which is illustrated in the various figures and drawings.
The invention provides a novel low-cost anesthetic sensing optical microfluidic chip system with molecularly imprinted biosensor. With this anesthetic sensing optical microfluidic chip system, a real-time propofol concentration detection can be achieved and the propofol concentration can be adjusted according to the result of the real-time propofol concentration detection. Therefore, the doctor can clinically control the propofol concentration more accurately and the safety of the patient can be further ensured.
An embodiment of the present invention is an anesthetic sensing optical microfluidic chip system. Please refer to
As shown in
In practical applications, the light source 10 can be a laser diode; the substrate 120 of the biochip 12 can be made of plastic material; the detector 14 can be a photodetector; the processor 16 can be a computer; the molecularly imprinted biosensor 122 can be made of polymer; the micro-channel 124 can be in the form of U. However, it should be noticed that the above-mentioned conditions are only examples, and there are still other possibilities, not limited to these cases.
Please refer to
It should be noticed that there are imprinted sites located on the surface of the molecularly imprinted biosensor 122, therefore, when the sample including anesthetic molecules flows through a surface of the molecularly imprinted biosensor 122, some of the anesthetic molecules will be captured by the imprinted sites located on the surface of the molecularly imprinted biosensor 122. At this time, the molecularly imprinted biosensor 122 becomes as a sample to be light-detected, and it is ready to be light-detected. In fact, the anesthetic molecules can be the propofol (2,6-di-isopropylphenol) molecules, but not limited to this case.
Then, the anesthetic sensing optical microfluidic chip system 1 will start to detect the anesthetic concentration of the anesthetic molecules captured on the molecularly imprinted biosensor 122. In the anesthetic sensing optical microfluidic chip system 1, the light source 10 will emit a sensing light to the plastic biochip 12. In fact, since propofol can be detected at the sensing light of 655 nm wavelength, the light source 10 can emit the sensing light of 655 nm wavelength, but not limited to this case.
As shown in
In practical applications, the detecting result generated by the detector 14 can relate to a measured voltage drop of the detector 14, and the measured voltage drop of the detector 14 can relate to the anesthetic concentration of the light-detected sample.
Please refer to
Please refer to
When the anesthetic molecules 3 are injected into the micro-channel 124 and flow through the surface of the molecularly imprinted biosensor 122 located in the micro-channel 124, some of the anesthetic molecules 3 will be captured by the imprinted sites 2, as shown in
Please refer to
Please refer to
Please refer to
In practical applications, the anesthetic sensing optical microfluidic chip system 1 can further include a display (not shown in the figures). The display is coupled to the processor 16, if the processor 16 detects that the anesthetic concentration of the sample is over a default threshold value, the display will show a warning message, so that the doctor can control the propofol concentration in-time according to the warning message shown on the display.
To sum up, the novel low-cost anesthetic sensing optical microfluidic chip system with molecularly imprinted biosensor disclosed by this invention has many advantages of compact size, high sensitivity, low cost, and fast response. With this anesthetic sensing optical microfluidic chip system, a real-time propofol concentration detection can be achieved and the propofol concentration can be also adjusted according to the result of the real-time propofol concentration detection.
Additionally, since the biochip used in the anesthetic sensing optical microfluidic chip system is cheap and can be disposable, the mutual contamination occurred between several samples in the same large-scale liquid chromatography and/or gas chromatography can be effectively avoided. By doing so, the doctor can clinically control the propofol concentration more accurately and the safety of the patient can be further ensured.
Although the present invention has been illustrated and described with reference to the preferred embodiment thereof, it should be understood that it is in no way limited to the details of such embodiment but is capable of numerous modifications within the scope of the appended claims.